The role of disclosures: helping to understand oncology clinical trial endpoints

18 May 2023 - FDA researchers wanted to see whether consumers understand oncology endpoints in DTC television ads, and whether disclosures ...

Read more →

Progression-free survival: it is time for a new name

1 March 2022 - Progression-free survival refers to the time from randomisation or initiation of treatment to the occurrence of disease ...

Read more →

Use of real world evidence to support FDA approval of oncology drugs

8 October 2020 - Real world evidence has gained increased attention in recent years as a complement to traditional clinical trials.  ...

Read more →

Demystifying the estimand framework: a case study using patient-reported outcomes in oncology

1 October 2020 - Patient-reported outcome measures describe how a patient feels or functions and are increasingly being used in benefit–risk ...

Read more →

Five predictions for AI and real world data in oncology

14 August 2018 - As progress in oncology care is advancing faster than ever -- especially due to the work ...

Read more →

FDA officials call for including adolescents in adult oncology trials

20 December 2016 - A team of officials at the US FDA are calling for a "culture shift" by drug ...

Read more →

Bristol-Myers Squibb’s Opdivo (nivolumab) receives breakthrough therapy designation from U.S. Food and Drug Administration for advanced renal cell carcinoma

16 September 2015 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

Read more →